₹344.28
Above FV▼ -38.3% against the close used
Model range ₹97.67 – ₹511.97
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear₹97.67Fair value₹344.28Bull₹511.97
FairClose
52-week traded range
52W low ₹349.5552W high ₹649.35
The 52-week range is measured from the stored price history, not estimated.
Trading above the consensus fair value
Thyrocare Tech Ltd closed at ₹557.70, 62.0% above the consensus fair value of ₹344.28 drawn from 9 valuation models.
Financial DNA score 64/100 — Good. P/E of 48.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
₹250.52
-55.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹97.67
-82.5%
√(22.5 × EPS × BVPS)
EPS=10.24, BVPS=41.4 · outside Graham range (P/E 48.4, P/B 13.5) — asset-light, treat as a rough floor
P/E Fair Value
₹430.59
-22.8%
EPS × 42.05x (sector P/E)
EPS=10.24, Sector P/E=42.05x
Peter Lynch (PEG)
₹256.00
-54.1%
EPS × Growth% (PEG = 1 is fair)
EPS=10.24, g=25%
EV/EBITDA
₹366.21
-34.3%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=3.22B
Dividend Discount (DDM)
₹511.97
-8.2%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=9.48, r=10%, g=8%
Book Value (P/B)
₹231.86
-58.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=41.4, ROE=28.4%, g=6%, r=10%
Reverse DCF
₹557.70
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 20.7% | Historical: 25%
Margin of Safety
₹194.70
-65.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=259.59, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.